{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:30:27Z","timestamp":1791138627668,"version":"4.1.0"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Carlos III Health Institute, Spain"},{"name":"Ministry of Economy and Competitivity"},{"name":"Xunta de Galicia (Isidro Parga Pondal Program and Competitive"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.ejpb.2015.02.019","type":"journal-article","created":{"date-parts":[[2015,2,25]],"date-time":"2015-02-25T21:44:59Z","timestamp":1424900699000},"page":"279-293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":173,"special_numbering":"PB","title":["Nanotherapies for the treatment of ocular diseases"],"prefix":"10.1016","volume":"95","author":[{"given":"S.","family":"Reimondez-Troiti\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Csaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"de la Fuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2015.02.019_b0005","first-page":"464","article-title":"Demonstration of the mucous layer of the tear film by electron microscopy","volume":"26","author":"Nichols","year":"1985","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.019_b0010","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jtos.2014.01.004","article-title":"Interfacial phenomena and the ocular surface","volume":"12","author":"Ya\u00f1ez-Soto","year":"2014","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.ejpb.2015.02.019_b0015","doi-asserted-by":"crossref","unstructured":"C.G. Wilson, L.E. Tan, Nanostructures overcoming the ocular barrier: physiological considerations and mechanistic issues, in: Nanostructures Overcoming Ocul. Barrier Physiol. Considerations Mech. Issues, 2012, pp. 173\u2013189.","DOI":"10.1039\/9781849735292-00173"},{"key":"10.1016\/j.ejpb.2015.02.019_b0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2174\/1389200043335342","article-title":"Role of metabolism in ocular drug delivery","volume":"5","author":"Duvvuri","year":"2004","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejpb.2015.02.019_b0025","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0039-6257(93)90141-S","article-title":"Minimizing systemic absorption of topically administered ophthalmic drugs","volume":"37","author":"Urtti","year":"1993","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.019_b0030","first-page":"1181","article-title":"Diffusion of high molecular weight compounds through sclera","volume":"41","author":"Ambati","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.019_b0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0014-4835(77)90282-2","article-title":"A study of the transfer of amino acids across the endothelium of the rabbit cornea","volume":"24","author":"Riley","year":"1977","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejpb.2015.02.019_b0040","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3109\/02713689008999587","article-title":"Lactate-proton cotransport in rabbit corneal epithelium","volume":"9","author":"Bonanno","year":"1990","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.ejpb.2015.02.019_b0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0169-409X(95)00010-5","article-title":"Ocular absorption following topical delivery","volume":"16","author":"J\u00e4rvinen","year":"1995","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.02.019_b0050","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1167\/iovs.02-1142","article-title":"Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines","volume":"44","author":"Dey","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.019_b0055","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/mt.2009.181","article-title":"Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous","volume":"17","author":"Dalkara","year":"2009","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.ejpb.2015.02.019_b0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/1872211308666140130093301","article-title":"Drug delivery to the back of the eye following topical administration: an update on research and patenting activity","volume":"8","author":"Boddu","year":"2014","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"10.1016\/j.ejpb.2015.02.019_b0065","first-page":"684","article-title":"Paracellular permeability of corneal and conjunctival epithelia","volume":"30","author":"Huang","year":"1989","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.019_b0070","doi-asserted-by":"crossref","first-page":"675","DOI":"10.4103\/0250-474X.84575","article-title":"Nano-vectors for the ocular delivery of nucleic acid-based therapeutics","volume":"72","author":"Khar","year":"2010","journal-title":"Ind. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.02.019_b0075","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijpharm.2014.02.038","article-title":"A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases","volume":"465","author":"Apaolaza","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0080","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejpb.2015.02.019_b0085","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1517\/17425240902762818","article-title":"Chitosan nanoparticles for drug delivery to the eye","volume":"6","author":"Paolicelli","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2015.02.019_b0090","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.addr.2009.11.026","article-title":"Chitosan-based nanostructures: a delivery platform for ocular therapeutics","volume":"62","author":"de la Fuente","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.02.019_b0095","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/jphp.12249","article-title":"Advances in ophthalmic drug delivery","volume":"66","author":"Singh","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.02.019_b0100","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jphp.12132","article-title":"Topical delivery of ocular therapeutics: carrier systems and physical methods","volume":"66","author":"Souza","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.02.019_b0105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0378-5173(85)90007-9","article-title":"Ocular disposition of poly-hexyl-2-cyano[3-14C]acrylate nanoparticles in the albino rabbit","volume":"23","author":"Wood","year":"1985","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0378-5173(86)90053-0","article-title":"Enhancement of the myotic response of rabbits with pilocarpine-loaded polybutylcyanoacrylate nanoparticles","volume":"33","author":"Harmia","year":"1986","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/02652048609049580","article-title":"A solid colloidal drug delivery system for the eye: encapsulation of pilocarpin in nanoparticles","volume":"3","author":"Harmia","year":"1986","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejpb.2015.02.019_b0120","doi-asserted-by":"crossref","DOI":"10.1111\/j.2042-7158.1991.tb03534.x","article-title":"Improvement of ocular penetration of amikacin sulphate by association to poly(butylcyanoacrylate) nanoparticles","author":"Losa","year":"1991","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.02.019_b0125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1023\/A:1018977130559","article-title":"Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol","volume":"10","author":"Losa","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.02.019_b0130","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.2042-7158.1996.tb03911.x","article-title":"Improved ocular bioavailability of indomethacin by novel ocular drug carriers","volume":"48","author":"Calvo","year":"1996","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.02.019_b0135","doi-asserted-by":"crossref","unstructured":"R.E. Stratford, D.C. Yang, M.A. Redell, V.H. Lee, Ocular distribution of liposome-encapsulated epinephrine and inulin in the albino rabbit, Curr. Eye Res. 2 (n.d.) 377\u2013386. http:\/\/dx.doi.org\/10.3109\/02713688209000783.","DOI":"10.3109\/02713688209000783"},{"key":"10.1016\/j.ejpb.2015.02.019_b0140","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0378-5173(83)90075-3","article-title":"Effects of topically applied liposomes on disposition of epinephrine and inulin in the albino rabbit eye","volume":"13","author":"Stratford","year":"1983","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0145","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijpharm.2009.06.020","article-title":"Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery","volume":"379","author":"Li","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0150","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3109\/03639040903099751","article-title":"Mucoadhesive liposomes as ocular delivery system: physical, microbiological, and in vivo assessment","volume":"36","author":"Mehanna","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0155","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/jps.22422","article-title":"Design and evaluation of controlled-release niosomes and discomes for naltrexone hydrochloride ocular delivery","volume":"100","author":"Abdelkader","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.02.019_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10717544.2014.943336","article-title":"Liposomes in topical ophthalmic drug delivery: an update","volume":"7544","author":"Agarwal","year":"2014","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2015.02.019_b0165","first-page":"220","article-title":"Liposomes in topical drug delivery","volume":"22","author":"Schaeffer","year":"1982","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.019_b0170","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0378-5173(99)00265-3","article-title":"Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery","volume":"190","author":"Nagarsenker","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0175","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/10837450903479988","article-title":"Ocular ciprofloxacin hydrochloride mucoadhesive chitosan-coated liposomes","volume":"16","author":"Abdelbary","year":"2011","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2015.02.019_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/pt0801001","article-title":"Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies","volume":"8","author":"Hathout","year":"2007","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ejpb.2015.02.019_b0185","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jconrel.2009.02.020","article-title":"Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye","volume":"136","author":"Hironaka","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.02.019_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2003.09.016","article-title":"Vesicular systems in ocular drug delivery: an overview","volume":"269","author":"Kaur","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0195","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijpharm.2007.01.019","article-title":"Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor","volume":"338","author":"Aggarwal","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0200","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1208\/s12249-011-9643-9","article-title":"Nanovesicular formulation of brimonidine tartrate for the management of glaucoma, vitro and in vivo evaluation","volume":"12","author":"Maiti","year":"2011","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ejpb.2015.02.019_b0205","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000267160","article-title":"A submicron emulsion as ocular vehicle for delta-8-tetrahydrocannabinol: effect on intraocular pressure in rabbits","volume":"24","author":"Muchtar","year":"1992","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.ejpb.2015.02.019_b0210","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0168-3659(96)01503-9","article-title":"Ex-vivo permeation study of indomethacin from a submicron emulsion through albino rabbit cornea","volume":"44","author":"Muchtar","year":"1997","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.02.019_b0215","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0168-3659(98)00107-2","article-title":"Evaluation of a positively charged submicron emulsion of piroxicam on the rabbit corneum healing process following alkali burn","volume":"57","author":"Klang","year":"1999","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.02.019_b0220","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0378-5173(99)00106-4","article-title":"Miotic effect and irritation potential of pilocarpine prodrug incorporated into a submicron emulsion vehicle","volume":"184","author":"Sznitowska","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0225","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0939-6411(98)00098-8","article-title":"Studies on the effect of pilocarpine incorporation into a submicron emulsion on the stability of the drug and the vehicle","volume":"47","author":"Zurowska-Pryczkowska","year":"1999","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0230","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1081\/PDT-100102035","article-title":"Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution","volume":"5","author":"Klang","year":"2000","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2015.02.019_b0235","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0378-5173(00)00443-9","article-title":"Increased partitioning of pilocarpine to the oily phase of submicron emulsion does not result in improved ocular bioavailability","volume":"202","author":"Sznitowska","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0240","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1208\/s12249-009-9268-4","article-title":"Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride","volume":"10","author":"Ammar","year":"2009","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ejpb.2015.02.019_b0245","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijpharm.2012.10.015","article-title":"Development of O\/W nanoemulsions for ophthalmic administration of timolol","volume":"440","author":"Gallarate","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0250","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jphp.12075","article-title":"Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery","volume":"66","author":"Daull","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.02.019_b0255","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.addr.2008.09.002","article-title":"Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery","volume":"60","author":"Jiao","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.02.019_b0260","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jconrel.2005.11.020","article-title":"W\/O microemulsions for ocular delivery: evaluation of ocular irritation and precorneal retention","volume":"111","author":"Alany","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.02.019_b0265","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0168-3659(85)90057-4","article-title":"Ocular therapy with nanoparticulate systems for controlled drug delivery","volume":"2","author":"Gurny","year":"1985","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.02.019_b0270","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3109\/02652049109021873","article-title":"Studies on the transport pathway of PBCA nanoparticles in ocular tissues","volume":"8","author":"Zimmer","year":"1991","journal-title":"J. Microemcapsul."},{"key":"10.1016\/j.ejpb.2015.02.019_b0275","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0378-5173(01)00760-8","article-title":"Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A","volume":"224","author":"De Campos","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0280","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1016\/S0142-9612(02)00080-7","article-title":"Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application","volume":"23","author":"Pignatello","year":"2002","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.02.019_b0285","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.carbpol.2006.01.020","article-title":"Preparation of cholesterol-modified chitosan self-aggregated nanoparticles for delivery of drugs to ocular surface","volume":"65","author":"Yuan","year":"2006","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2015.02.019_b0290","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2174\/1874104500802010066","article-title":"Transcorneal permeation in a corneal device of non-steroidal anti-inflammatory drugs in drug delivery systems","volume":"2","author":"Valls","year":"2008","journal-title":"Open Med. Chem. J."},{"key":"10.1016\/j.ejpb.2015.02.019_b0295","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1167\/iovs.07-1077","article-title":"Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy","volume":"49","author":"De La Fuente","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.019_b0300","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1021\/mp900279c","article-title":"Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin\/prednisolone bitherapy","volume":"7","author":"Ibrahim","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0305","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.nano.2009.10.004","article-title":"Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery","volume":"6","author":"Gupta","year":"2010","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.ejpb.2015.02.019_b0310","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/1061186X.2010.504268","article-title":"Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery","volume":"19","author":"Gupta","year":"2011","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejpb.2015.02.019_b0315","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/02652048.2010.523794","article-title":"Diclofenac-loaded Eudragit S100 nanosuspension for ophthalmic delivery","volume":"28","author":"Ahuja","year":"2011","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejpb.2015.02.019_b0320","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jconrel.2011.01.010","article-title":"Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: cellular toxicity, uptake, and kinetic studies","volume":"151","author":"Aksungur","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.02.019_b0325","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/jphp.12089","article-title":"Rapamycin-loaded poly(\u03b5-caprolactone)-poly(ethylene glycol)-poly(\u03b5-caprolactone) nanoparticles: preparation, characterization and potential application in corneal transplantation","volume":"66","author":"Zhang","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.02.019_b0330","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ijpharm.2007.07.045","article-title":"Preparation of rapamycin-loaded chitosan\/PLA nanoparticles for immunosuppression in corneal transplantation","volume":"349","author":"Yuan","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0335","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3109\/10611860903450023","article-title":"Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation","volume":"18","author":"Wadhwa","year":"2010","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejpb.2015.02.019_b0340","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1248\/cpb.59.272","article-title":"Chitosan nanoparticles of 5-fluorouracil for ophthalmic delivery: characterization, in-vitro and in-vivo study","volume":"59","author":"Nagarwal","year":"2011","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejpb.2015.02.019_b0345","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2174\/1567201811310050001","article-title":"Betaxolol hydrochloride loaded chitosan nanoparticles for ocular delivery and their anti-glaucoma efficacy","volume":"10","author":"Jain","year":"2013","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ejpb.2015.02.019_b0350","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.carbpol.2013.10.079","article-title":"In situ gelling dorzolamide loaded chitosan nanoparticles for the treatment of glaucoma","volume":"102","author":"Katiyar","year":"2014","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2015.02.019_b0355","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1023\/B:PHAM.0000026432.75781.cb","article-title":"Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity","volume":"21","author":"De Campos","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.02.019_b0360","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1167\/iovs.05-0495","article-title":"Chitosan nanoparticles as a potential drug delivery system for the ocular surface. Toxicity, uptake mechanism and in vivo tolerance","volume":"47","author":"De Salamanca","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.019_b0365","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.biomaterials.2006.11.028","article-title":"Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP)","volume":"28","author":"Diebold","year":"2007","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.02.019_b0370","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/gt.2008.16","article-title":"Bioadhesive hyaluronan-chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue","volume":"15","author":"de la Fuente","year":"2008","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejpb.2015.02.019_b0375","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/ICO.0b013e3181bd9eee","article-title":"Ocular tolerance to a topical formulation of hyaluronic acid and chitosan-based nanoparticles","author":"Contreras-Ruiz","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.ejpb.2015.02.019_b0380","first-page":"279","article-title":"Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells","volume":"17","author":"Contreras-Ruiz","year":"2011","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ejpb.2015.02.019_b0385","first-page":"564","article-title":"Size-dependent internalisation of folate-decorated nanoparticles via the pathways of clathrin and caveolae-mediated endocytosis in ARPE-19 cells","author":"Suen","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.02.019_b0390","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0378-5173(94)90179-1","article-title":"Study of the mechanism of interaction of poly(\u03b5-caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy","volume":"103","author":"Calvo","year":"1994","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0395","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1023\/A:1016015803611","article-title":"Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A","volume":"13","author":"Calvo","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.02.019_b0400","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0378-5173(97)00083-5","article-title":"Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers","volume":"153","author":"Calvo","year":"1997","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0405","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s003960050050","article-title":"Development of positively charged colloidal drug carriers: chitosan-coated polyester nanocapsules and submicron emulsions","volume":"275","author":"Calvo","year":"1997","journal-title":"Colloid Polym. Sci."},{"key":"10.1016\/j.ejpb.2015.02.019_b0410","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s12272-001-1266-6","article-title":"Chitosan based nanocarriers for indomethacin ocular delivery","volume":"31","author":"Badawi","year":"2008","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.02.019_b0415","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1248\/bpb.32.1266","article-title":"Mucoadhesive properties of chitosan-coated ophthalmic lipid emulsion containing indomethacin in tear fluid","volume":"32","author":"Yamaguchi","year":"2009","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejpb.2015.02.019_b0420","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijpharm.2010.10.013","article-title":"Nanostructured lipid carrier (NLC) coated with chitosan oligosaccharides and its potential use in ocular drug delivery system","volume":"403","author":"Luo","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0425","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0928-0987(03)00178-7","article-title":"The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa","volume":"20","author":"De Campos","year":"2003","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.02.019_b0430","doi-asserted-by":"crossref","first-page":"17028","DOI":"10.1039\/C3RA47370H","article-title":"Polymeric micelles as drug delivery vehicles","volume":"4","author":"Ahmad","year":"2014","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejpb.2015.02.019_b0435","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0378-5173(88)90060-9","article-title":"Solubilization of tropicamide by poloxamers: physicochemical data and activity data in rabbits and humans","volume":"43","author":"Saettone","year":"1988","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(00)00508-1","article-title":"Ketorolac entrapped in polymeric micelles: preparation, characterisation and ocular anti-inflammatory studies","volume":"209","author":"Gupta","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0445","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1023\/A:1013671819604","article-title":"Cyclosporine A formulation affects its ocular distribution in rabbits","volume":"19","author":"Kuwano","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.02.019_b0450","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijpharm.2003.11.032","article-title":"Micellar solutions of triblock copolymer surfactants with pilocarpine","volume":"272","author":"Pepi\u0107","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0455","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijpharm.2009.05.028","article-title":"Polyhydroxyethylaspartamide-based micelles for ocular drug delivery","volume":"378","author":"Civiale","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0460","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3109\/02713683.2010.508867","article-title":"In vivo evaluation of novel nanoparticles containing dexamethasone for ocular drug delivery on rabbit eye","volume":"35","author":"Rafie","year":"2010","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.ejpb.2015.02.019_b0465","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ijpharm.2011.01.004","article-title":"Ocular biocompatibility of novel Cyclosporin A formulations based on methoxy poly(ethylene glycol)-hexylsubstituted poly(lactide) micelle carriers","volume":"416","author":"Di Tommaso","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0470","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/jop.2013.0157","article-title":"Aqueous nanomicellar formulation for topical delivery of biotinylated lipid prodrug of acyclovir: formulation development and ocular biocompatibility","volume":"30","author":"Vadlapudi","year":"2014","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2015.02.019_b0475","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1021\/bm4018879","article-title":"Dithiol-PEG-PDLLA micelles: preparation and evaluation as potential topical ocular delivery vehicle","volume":"15","author":"Yang","year":"2014","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ejpb.2015.02.019_b0480","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2014.03.026","article-title":"PEG-PLGA copolymers: their structure and structure-influenced drug delivery applications","volume":"183","author":"Zhang","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.02.019_b0485","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/mabi.201000388","article-title":"Advances in mucoadhesion and mucoadhesive polymers","volume":"11","author":"Khutoryanskiy","year":"2011","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.ejpb.2015.02.019_b0490","first-page":"365","article-title":"Polymeric micelles in ocular drug delivery: rationale, strategies and challenges","volume":"26","author":"Pepic","year":"2012","journal-title":"Chem. Biochem. Eng. Q."},{"key":"10.1016\/j.ejpb.2015.02.019_b0495","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1126\/science.1078192","article-title":"Micellar nanocontainers distribute to defined cytoplasmic organelles","volume":"300","author":"Savi\u0107","year":"2003","journal-title":"Science (80-.)"},{"key":"10.1016\/j.ejpb.2015.02.019_b0500","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejpb.2012.02.014","article-title":"Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies","volume":"81","author":"Di Tommaso","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0505","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/jop.2012.0232","article-title":"Dendrimer nanoparticles for ocular drug delivery","volume":"29","author":"Kambhampati","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2015.02.019_b0510","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/jphp.12104","article-title":"Dendrimers for gene delivery \u2013 a potential approach for ocular therapy?","volume":"66","author":"Chaplot","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.02.019_b0515","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2004.09.015","article-title":"Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide","volume":"102","author":"Vandamme","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.02.019_b0520","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1021\/bm7008203","article-title":"Cytotoxicity of polypropylenimine dendrimer conjugates on cultured endothelial cells","volume":"8","author":"Stasko","year":"2007","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ejpb.2015.02.019_b0525","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1039\/b904746h","article-title":"Antibacterial activity and cytotoxicity of PEGylated poly(amidoamine) dendrimers","volume":"5","author":"Lopez","year":"2009","journal-title":"Mol. BioSyst."},{"key":"10.1016\/j.ejpb.2015.02.019_b0530","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ejmech.2009.10.017","article-title":"Designing dendrimers for ocular drug delivery","volume":"45","author":"Spataro","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejpb.2015.02.019_b0535","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1167\/iovs.10-5388","article-title":"Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin","volume":"51","author":"Durairaj","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.019_b0540","doi-asserted-by":"crossref","first-page":"7595","DOI":"10.1021\/nn301873v","article-title":"Hybrid dendrimer hydrogel\/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration","volume":"6","author":"Yang","year":"2012","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2015.02.019_b0545","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.nano.2011.08.018","article-title":"Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs","volume":"8","author":"Holden","year":"2012","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.ejpb.2015.02.019_b0550","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ejmech.2008.06.012","article-title":"PEGylated PPI dendritic architectures for sustained delivery of H2 receptor antagonist","volume":"44","author":"Gajbhiye","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejpb.2015.02.019_b0555","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1007\/s11095-006-9122-2","article-title":"Transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers: influence of size, charge and fluorescent labeling","volume":"23","author":"Kitchens","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.02.019_b0560","first-page":"295","article-title":"Nanocrystal technology, drug delivery and clinical applications","volume":"3","author":"Junghanns","year":"2008","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2015.02.019_b0565","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jconrel.2014.03.030","article-title":"Engineered nanocrystal technology: in-vivo fate, targeting and applications in drug delivery","volume":"183","author":"Pawar","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.02.019_b0570","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijpharm.2007.03.011","article-title":"Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs","volume":"340","author":"Kassem","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0575","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2010.10.007","article-title":"Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling","volume":"149","author":"Ali","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.02.019_b0580","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijpharm.2014.03.048","article-title":"Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo","volume":"467","author":"Tuomela","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0585","doi-asserted-by":"crossref","first-page":"526","DOI":"10.2165\/00003495-199652040-00006","article-title":"Common ocular infections. A prescriber\u2019s guide","volume":"52","author":"Donahue","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.ejpb.2015.02.019_b0590","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2011.07.002","article-title":"\u201cNanoantibiotics\u201d: a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era","volume":"156","author":"Huh","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.02.019_b0595","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0378-5173(02)00080-7","article-title":"Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin","volume":"238","author":"Cavalli","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0600","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/jbm.a.34467","article-title":"Part II: Enhancement of transcorneal delivery of gatifloxacin by solid lipid nanoparticles in comparison to commercial aqueous eye drops","volume":"101A","author":"Kalam","year":"2013","journal-title":"J. Biomed. Mater. Res. \u2013 Part A"},{"key":"10.1016\/j.ejpb.2015.02.019_b0605","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0168-3659(99)00192-3","article-title":"Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption","volume":"63","author":"Law","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.02.019_b0610","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1755-3768.2009.01584.x","article-title":"Liposomes as an ocular delivery system of fluconazole: in-vitro studies","volume":"88","author":"Habib","year":"2010","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.019_b0615","doi-asserted-by":"crossref","first-page":"E371","DOI":"10.1208\/aapsj0903044","article-title":"Preparation and ocular pharmacokinetics of ganciclovir liposomes","volume":"9","author":"Shen","year":"2007","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2015.02.019_b0620","doi-asserted-by":"crossref","first-page":"173","DOI":"10.17925\/EOR.2012.06.03.173","article-title":"Current use of non-steroidal anti-inflammatory drugs in the treatment of ocular inflammation related to cataract surgery","author":"Donnenfeld","year":"2012","journal-title":"Eur. Ophthalmic Rev."},{"key":"10.1016\/j.ejpb.2015.02.019_b0625","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0928-0987(02)00057-X","article-title":"Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen","volume":"16","author":"Pignatello","year":"2002","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.02.019_b0630","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijpharm.2011.03.041","article-title":"Novel NSAIDs ophthalmic formulation: flurbiprofen axetil emulsion with low irritancy and improved anti-inflammation effect","volume":"412","author":"Shen","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0635","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1002\/jps.22137","article-title":"A nonionic surfactant\/chitosan micelle system in an innovative eye drop formulation","volume":"99","author":"Pepi\u0107","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.02.019_b0640","first-page":"1757","article-title":"Preparation and in-vitro evaluation of diclofenac sodium niosomal formulations","volume":"4","author":"Marwa","year":"2013","journal-title":"Int. J. Pharm. Sci. Res."},{"key":"10.1016\/j.ejpb.2015.02.019_b0645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2012.04.063","article-title":"Conjunctival and corneal tolerability assessment of ocular naltrexone niosomes and their ingredients on the hen\u2019s egg chorioallantoic membrane and excised bovine cornea models","volume":"432","author":"Abdelkader","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0650","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1755-3768.1993.tb07146.x","article-title":"Ocular fatigue is the major symptom of dry eye","volume":"71","author":"Toda","year":"1993","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.019_b0655","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2147\/OPTH.S6225","article-title":"The effects of lubricant eye drops on visual function as measured by the Inter-blink interval Visual Acuity Decay test","volume":"3","author":"Torkildsen","year":"2009","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.019_b0660","first-page":"581","article-title":"Diagnosis of dry eye disease and emerging technologies","volume":"8","author":"Zeev","year":"2014","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.019_b0665","first-page":"1004","article-title":"Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sj\u00f6gren syndrome","volume":"43","author":"Arg\u00fceso","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.019_b0670","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/jcp.24398","article-title":"The cellular mechanisms of dry eye: from pathogenesis to treatment","volume":"228","author":"Mantelli","year":"2013","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejpb.2015.02.019_b0675","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.exer.2008.04.002","article-title":"Hyaluronic acid coated poly-\u03b5-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea","volume":"87","author":"Yenice","year":"2008","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejpb.2015.02.019_b0680","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ijpharm.2010.10.008","article-title":"Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: improving in vivo ocular distribution","volume":"402","author":"Shen","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0685","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijpharm.2012.08.016","article-title":"Cyclosporin nanosphere formulation for ophthalmic administration","volume":"437","author":"Khan","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0690","first-page":"3791","article-title":"Supercritical fluid-mediated liposomes containing cyclosporin A for the treatment of dry eye syndrome in a rabbit model: comparative study with the conventional cyclosporin A emulsion","volume":"9","author":"Karn","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2015.02.019_b0695","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/mabi.201100005","article-title":"Hybrid nanoparticle design based on cationized gelatin and the polyanions dextran sulfate and chondroitin sulfate for ocular gene therapy","volume":"11","author":"Zorzi","year":"2011","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.ejpb.2015.02.019_b0700","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1021\/mp200155t","article-title":"Expression of MUC5AC in ocular surface epithelial cells using cationized gelatin nanoparticles","volume":"8","author":"Zorzi","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0705","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/gt.2012.56","article-title":"A nanomedicine to treat ocular surface inflammation: performance on an experimental dry eye murine model","volume":"20","author":"Contreras-Ruiz","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejpb.2015.02.019_b0710","first-page":"CD006539","article-title":"Neuroprotection for treatment of glaucoma in adults","volume":"2","author":"Sena","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejpb.2015.02.019_b0715","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(04)16257-0","article-title":"Primary open-angle glaucoma","volume":"363","author":"Weinreb","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2015.02.019_b0720","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/ICU.0b013e32835cfe92","article-title":"Nanotechnology and glaucoma: little particles for a big disease","volume":"24","author":"Pita-Thomas","year":"2013","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.019_b0725","first-page":"2513","article-title":"Gene therapy for glaucoma: treating a multifaceted, chronic disease","volume":"43","author":"Borr\u00e1s","year":"2002","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.019_b0730","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.exer.2008.08.011","article-title":"Glaucoma-associated myocilin: a better understanding but much more to learn","volume":"88","author":"Resch","year":"2009","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejpb.2015.02.019_b0735","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1093\/hmg\/ddq146","article-title":"Overexpression of optineurin E50K disrupts Rab8 interaction and leads to a progressive retinal degeneration in mice","volume":"19","author":"Chi","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejpb.2015.02.019_b0740","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021967","article-title":"Genome-wide linkage scan for primary open angle glaucoma: influences of ancestry and age at diagnosis","volume":"6","author":"Crooks","year":"2011","journal-title":"Plos One"},{"key":"10.1016\/j.ejpb.2015.02.019_b0745","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ophtha.2011.11.003","article-title":"Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement","volume":"119","author":"Chang","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2015.02.019_b0750","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","article-title":"The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators","volume":"130","author":"Investigators","year":"2000","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.019_b0755","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1208\/s12249-011-9675-1","article-title":"Brimonidine Tartrate\u2013Eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation","volume":"12","author":"Bhagav","year":"2011","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ejpb.2015.02.019_b0760","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1002\/app.35229","article-title":"Pilocarpine-loaded poly(dl-lactic-co-glycolic acid) nanoparticles as potential candidates for controlled drug delivery with enhanced ocular pharmacological response","volume":"124","author":"Nair","year":"2012","journal-title":"J. Appl. Polym. Sci."},{"key":"10.1016\/j.ejpb.2015.02.019_b0765","first-page":"2483","article-title":"Design of cationic nanostructured heterolipid matrices for ocular delivery of methazolamide","volume":"7","author":"Youshia","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2015.02.019_b0770","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0378-5173(99)00348-8","article-title":"Prolonged effect of liposomes encapsulating pilocarpine HCl in normal and glaucomatous rabbits","volume":"198","author":"Monem","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0775","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/bdd.778","article-title":"The extended ocular hypotensive effect of positive liposomal cholesterol bound timolol maleate in glaucomatous rabbits","volume":"32","author":"Shafaa","year":"2011","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejpb.2015.02.019_b0780","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijpharm.2004.10.026","article-title":"Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system","volume":"290","author":"Aggarwal","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0785","doi-asserted-by":"crossref","first-page":"356","DOI":"10.4103\/0975-1483.71623","article-title":"Preparation and evaluation of nano-vesicles of brimonidine tartrate as an ocular drug delivery system","volume":"2","author":"Prabhu","year":"2010","journal-title":"J. Young Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0790","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijpharm.2005.09.023","article-title":"Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide","volume":"306","author":"Guinedi","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0795","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1211\/0022357044896","article-title":"Development of a topical niosomal preparation of acetazolamide: preparation and evaluation","volume":"56","author":"Aggarwal","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.02.019_b0800","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1208\/s12249-010-9388-x","article-title":"Dual-drug delivery system based on in situ gel-forming nanosuspension of forskolin to enhance antiglaucoma efficacy","volume":"11","author":"Gupta","year":"2010","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ejpb.2015.02.019_b0805","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1001\/archophthalmol.2010.172","article-title":"Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and usher syndrome","volume":"128","author":"Genead","year":"2010","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.019_b0810","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/bjo.2005.073817","article-title":"Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review","volume":"89","author":"Sivaprasad","year":"2005","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.019_b0815","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1006\/bbrc.1996.0326","article-title":"Gene transfer to the retina of rat by liposome eye drops","volume":"219","author":"Matsuo","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejpb.2015.02.019_b0820","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ijpharm.2012.07.024","article-title":"Liposomal diclofenac eye drop formulations targeting the retina: formulation stability improvement using surface modification of liposomes","volume":"436","author":"Fujisawa","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.019_b0825","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/smll.201303433","article-title":"Topical delivery of avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes","volume":"10","author":"Davis","year":"2014","journal-title":"Small"},{"key":"10.1016\/j.ejpb.2015.02.019_b0830","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40123-014-0021-z","article-title":"Ocular pharmacokinetics of a novel loteprednol etabonate 0.4% ophthalmic formulation","volume":"3","author":"Schopf","year":"2014","journal-title":"Ophthalmol. Ther."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115001010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115001010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T17:24:24Z","timestamp":1537809864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641115001010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":166,"alternative-id":["S0939641115001010"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.02.019","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanotherapies for the treatment of ocular diseases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}